- Home
- MCTR vs GNLX Comparison
MCTR vs GNLX Comparison
Compare MCTR & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCTR
- GNLX
- Stock Information
- Founded
- MCTR 2014
- GNLX 2001
- Country
- MCTR Hong Kong
- GNLX United States
- Employees
- MCTR N/A
- GNLX N/A
- Industry
- MCTR
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- MCTR
- GNLX Health Care
- Exchange
- MCTR NYSE
- GNLX Nasdaq
- Market Cap
- MCTR 87.5M
- GNLX 94.0M
- IPO Year
- MCTR 2025
- GNLX 2023
- Fundamental
- Price
- MCTR $4.72
- GNLX $2.42
- Analyst Decision
- MCTR
- GNLX Strong Buy
- Analyst Count
- MCTR 0
- GNLX 4
- Target Price
- MCTR N/A
- GNLX $17.75
- AVG Volume (30 Days)
- MCTR 9.0K
- GNLX 159.0K
- Earning Date
- MCTR 01-01-0001
- GNLX 05-06-2025
- Dividend Yield
- MCTR N/A
- GNLX N/A
- EPS Growth
- MCTR N/A
- GNLX N/A
- EPS
- MCTR 0.00
- GNLX N/A
- Revenue
- MCTR $4,453,234.00
- GNLX N/A
- Revenue This Year
- MCTR N/A
- GNLX N/A
- Revenue Next Year
- MCTR N/A
- GNLX N/A
- P/E Ratio
- MCTR $3,857.49
- GNLX N/A
- Revenue Growth
- MCTR N/A
- GNLX N/A
- 52 Week Low
- MCTR $3.76
- GNLX $1.60
- 52 Week High
- MCTR $12.00
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- MCTR N/A
- GNLX 43.88
- Support Level
- MCTR N/A
- GNLX $2.42
- Resistance Level
- MCTR N/A
- GNLX $2.78
- Average True Range (ATR)
- MCTR 0.00
- GNLX 0.24
- MACD
- MCTR 0.00
- GNLX 0.00
- Stochastic Oscillator
- MCTR 0.00
- GNLX 11.43
About MCTR CTRL GROUP LTD
CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.